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This spring, CDC Division of Tuberculosis Elimination (DTBE) staff members were 
involved in a variety of events, several held in conjunction with 2014 World TB Day, 
both here in Atlanta as well as in Washington, DC. 
 
The CDC Public Health Grand Rounds session for March focused on multidrug-resistant 
(MDR) TB and was presented by an internationally known MDR TB patient / 
spokesperson, as well as several TB experts from CDC and the World Health 
Organization. DTBE also hosted a Twitter chat, an event that engaged over 700 Twitter 
users. In addition, the annual World TB Day issue of the Morbidity and Mortality Weekly 
Report came out on March 20.  In this issue, DTBE published World TB Day — March 
24, 2014 and  Trends in Tuberculosis — United States, 2013, indicating that for 2013, a 
provisional total of 9,588 new TB cases were reported in the United States. There was 
also an article by staff of the Division of Global Migration and Quarantine, entitled 
Implementation of New TB Screening Requirements for U.S.-Bound Immigrants and 
Refugees —2007–2014. 
 
Every spring, CDC holds its Epidemic Intelligence Service (EIS) conference in Atlanta. 
This is an opportunity for current EIS officers to gain experience in reporting and 
presenting the results of their CDC work, for current and prior EIS officers to meet and 
network with others at CDC, and for incoming EIS officers to match up with a CDC 
program for their 2-year EIS assignment. Our Division successfully participates in this 
conference every year. This year the conference was held from April 28 to May 2 and, 
as usual, included a session on tuberculosis. Please see the report on the 2014 EIS 
conference in this issue. 
 
CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
(NCHHSTP) recognizes its employees for their accomplishments in an annual honor 
awards ceremony. A number of DTBE employees will be recognized at this year’s 
event: Julia Ershova, Sundari Mase, Kathryn Koski, and Brittany Moore, and several 
groups: DTBE’s TB Trials Consortium (TBTC) Study 33 Implementation Team, DTBE’s 
International Operations Research Training Course Coordinators, DTBE’s “Think Tank,” 
and several DTBE staff who were part of the Antibiotic Resistance Threat Report Team.  
 
These individuals and group members honored at the NCHHSTP awards ceremony 
then go on to be nominees for CDC honor awards. At this year’s annual CDC honor 
awards ceremony on May 13, the Antibiotic Resistance Threat Report Team received 
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the Excellence in Communications award. Congratulations to the DTBE members of the 
team for this high honor! 
 
The Advisory Council for the Elimination of Tuberculosis met in Atlanta June 9–10, 
2014. That meeting was followed by the 2014 National TB Conference, "Sharing the 
Vision of TB Elimination," held June 11–13, 2014, with pre-meetings on June 10 and 
post-meetings on June 13 in the afternoon. The meeting was located this year at the 
Grand Hyatt Atlanta in Buckhead. Invited participants for the conference included State 
and Big City TB Controllers, TB Medical Consultants, TB Nurse Consultants, TB 
Program Managers, TB epidemiologists, other front-line TB program staff, Regional 
Training and Medical Consultation Centers (RTMCC) leadership, and other partners 
engaged in TB control. The National Tuberculosis Controllers Association (NTCA) 
website (www.tbcontrollers.org) provided conference-related information, including the 
agenda and conference registration. I hope many of you were able to attend and benefit 
from the 2014 National TB Conference. We will have reports from the meeting in the 
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HIGHLIGHTS FROM STATE AND 
LOCAL PROGRAMS 
 
News from the National TB 
Controllers Association 
 
Change and growth in an organization can be 
exhilarating and it is easy to get caught up in the 
excitement of all that is new, especially when 
examining the possibilities!  However, despite the 
exciting evolution that the National TB Controllers 
Association (NTCA) is undergoing, we still 
experience the sadness and loss when one of 
our own decides to change paths, and that path 
leads them away. NTCA has experienced this 
continuum of responses during these last few 
months. 
 
Launch of the NTCA Epidemiology 
Section 
 
One of those exhilarating changes occurring 
within the NTCA is the establishment of a new 
Epidemiology Section. This section will be 
devoted to developing a professional “home” for 
those with graduate education, those with 
practical and professional experience, and those 
who share an interest in the epidemiology of 
tuberculosis and seek to become more educated 
consumers of the science. As we are increasingly 
aware, knowledge and expertise in TB 
epidemiology is essential to the work we do in 
local, state, and territorial TB programs. This new 
Section will likely become a vibrant and active 
one, and will contribute significantly to the work 
of NTCA in the same way that the two existing 
sections, the National TB Nurse Coalition 
(NTNC) and the National Society of TB Clinicians 
(NSTC), have done and continue to do.  
 
Dr. Shama Desai Ahuja was recently appointed 
as the first President of the Epidemiology 
Section. Shama has been instrumental in the 
work to establish this Section and authored the 
petition presented to the NTCA Board. Shama 
also was centrally involved in the planning of the 
session at the 2014 NTC devoted to the topic, 
Using Epidemiology to Inform Public Health 
Intervention in Key Populations, and presented 
on the successful approach taken by the New 
York City TB Program to integrate epidemiology 
into program decision-making.   
 
An inaugural meeting of this new Section was 
held Tuesday, June 10. This meeting was held in 
conjunction with the 2014 National TB 
Conference and was open to anyone interested 
in joining this section. For additional suggestions 
about the section, please feel free to contact 
Shama at sahuja@health.nyc.gov. 
 
On the loss side, significant leadership changes 
have occurred over the last few months in 
several state and big city TB programs.  Although 
we look forward to a close working relationship 
with those individuals named to carry on the work 
of their predecessors, we mourn the recent 
departures of two very active members of the 
NTCA organization:  Deb Sodt and Cristie 
Chessler. 
 
Minnesota’s Deb Sodt Retires 
 
Deb Sodt decided 2014 was the year to retire!  A 
perfect role model for today’s public health nurse, 
Deb has spent her professional life doing what 
she loves.  Deb was hired 20 years ago to be the 
first "Screening Coordinator" for the breast and 
cervical cancer control program, later known as 
SAGE, within the Minnesota Department of 
Public Health. From Deb’s supervisor, “Deb was 
TB 
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instrumental in getting the program off the 
ground, recruiting and training clinics to provide 
services to underserved women throughout the 
state.” Deb’s legacy still lives on as the program 
continues to provide healthcare services to low-
income women who are under- and uninsured. 
One estimate puts the number of women served 
at between 120,000 and 140,000!  
 
The legacy Deb leaves in TB control is no less 
significant, and can be measured in services to 
those within her own state who experience TB as 
well as in contributions to the national efforts at 
TB control. Over the years, Deb has contributed 
significantly to the efforts in domestic TB control 
by providing leadership to DTBE on the National 
TB indicators Project (NTIP), the Electronic 
Disease Notification (EDN) System, the 
Genotyping and Tuberculosis Genotyping 
information Management System (TB GIMS), 
and the TB Education and Training Network (TB 
ETN).   
As an NTCA Board member, Deb provided 
leadership to an organization composed of her 
colleagues and friends. Her quiet demeanor 
masks a quick wit, along with OCD-like 
organizational qualities that are the envy of those 
around her. Much of the credit for the 
establishment of the current Technical 
Instructions (TIs) 
introduced by 
CDC’s Division of 
Global Migration 
and Quarantine 
(DGMQ) can be 
attributed to Deb’s 
leadership and 
facilitation skills. 
She recognized a 
growing concern at 
the state level and 
worked with 




concern — just 
one of the many 
legacies she 




We recognize that, despite her retirement, Deb 
can’t stay away from an organization she dearly 
loves. We fully anticipate her continued active 
involvement with the NTCA and will be waiting 
with an extensive “to do” list for her upon her 
return.  
 
Utah’s Cristie Chesler Moves Up 
 
Another loss significantly affecting the NTCA is 
the recent promotion of Cristie Chesler, Utah’s 
TB Controller. Although a huge loss to NTCA and 
to domestic TB control, we are thrilled for the 
State of Utah and those with whom Cristie will 
work. Recognized for her success in running the 
state’s TB control program, Cristie has been 
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promoted to the position of Director of the Bureau 
of Epidemiology within the Utah Department of 
Health. In accepting this new position, Cristie 
vacated her position as both the Utah State TB 
Controller and the State Refugee Health 
Coordinator, positions she has held since 1999. 
During her tenure, the quality and availability of 
services for individuals diagnosed with TB 
disease increased significantly, and under her 
leadership, Utah became one of the first states to 
implement the Cohort Review Process. Cristie 
was instrumental in forming a statewide TB 
Advisory Committee; under her guidance, a 
contract for a secured tuberculosis unit for the 
isolation of homeless and/or court-ordered 
patients was negotiated and successfully 
executed. 
 
Cristie joined the NTCA Board in 2012 and 
became active in the Membership Committee 
and the Organizational Development/Strategic 
Planning Workgroup. Cristie’s commitment to the 
states with low-incidence rates of tuberculosis 
was evident. 
We don’t deny that we are thrilled for Deb and 
Cristie and support them in their new pursuits. 
However, we are saddened that they leave us as 
the organization is experiencing such 
transformative changes. We recognize their 
contributions to both the past and the future of 
NTCA, and wish them all the best. 
 
Welcome to New TB Control Staff 
 
With the losses of Deb and Cristie, there have 
been newly named TB Controllers in Minnesota 
and Utah. We welcome and look forward to 
working with- 
• Sarah Gordon, TB Controller/TB Unit 
Manager for the Minnesota Department of 
Health 
• Allyn Nakashima, MD, TB Controller with the 
Utah Department of Health 
 
In addition, we welcome the following new TB 
control staff and look forward to introducing them 
to the work of the NTCA and to their new TB 
colleagues: 
• Kimberly Fitzpatrick, Public Health Program 
Manager, Division of TB/STD with the 
Pennsylvania Department of Health 
• Molly Harrar, Program Administrator with the 
Philadelphia Department of Public Health 
• Janette Candido, TB program manager with 
the Illinois Department of Public Health 
 
—Submitted by Donna Hope Wegener 
and Jennifer Kanouse 
NTCA Central Office 
 
Round-up of 2014 World TB Day 
Activities 
 
CDC's Public Health Grand Rounds 
 
On March 18, CDC’s Public Health Grand 
Rounds session focused on multidrug-resistant 
(MDR) TB. This session was presented by three 
of CDC’s TB experts — Sarita Shah, MD, MPH, 
and Tom Shinnick, PhD, Division of Tuberculosis 
Elimination, and Tom Kenyon, MD, MPH, Center 
for Global Health — as well as Dalene von Delft, 
MBChB, founder of “TB Proof” and Christian 
Leinhardt, MD, DTM, MSc, PhD, a colleague 
from the World Health Organization. 
 
Dr. von Delft’s presentation began with a 
slideshow that told her personal story as a 
physician in South Africa who was diagnosed in 
2010 with MDR TB. For 18 months, she had to 
take 30 pills a day; 10 of these were to 
counteract the side effects of the TB drugs. 
Although she suffered some hearing loss, she 
was cured one year after being granted 
compassionate use of bedaquiline. 
 
Dr. Shah went on to discuss that MDR TB is 
particularly challenging in the low-resource 
settings where it is most often found. She and 
her fellow presenters shared that detection rates 
are low, and for those fortunate patients who are 
found and started on treatment, therapy 
completion rates are low as well. Fortunately, 
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there have been important advances recently in 
TB drugs and diagnostics. With the introduction 
of the MDR/RIF Xpert technology, health staff 
may now detect MDR TB in a matter of hours, 
and under field conditions where it is needed. In 
addition, clinicians now have limited access to 
the new drug bedaquiline which is effective 
against MDR TB. There are also a few other 
drugs for TB treatment in the pipeline. 
 
The take-away message of the Grand Rounds 
was that, despite good news — the availability of 
revolutionary tests that allow for faster diagnosis 
and of new drugs and regimens that offer better 
and safer treatment — that’s not the end of the 
story. Patients and providers must also be part of 
the solution. Patients must present when 
symptoms occur and complete treatment in a 
timely manner. Providers must diagnose and 
treat TB promptly and correctly, and use good 
infection control measures. Lastly, health 
systems must be strengthened, particularly in 
resource-limited settings, to improve access to 
quality diagnostics and treatment for all patients 
who may be at risk for MDR TB. 
 




—Reported by Ann Lanner 
Div of TB Elimination 
 
CDC’s World TB Day Twitter Chat 
 
World TB Day is observed across the globe with 
diverse activities and events. It presents an 
opportunity for CDC, our partners in state and 
local TB control programs, and others to raise 
awareness about TB by educating the public 
about the disease, sharing TB control successes, 
and highlighting ongoing barriers to TB control 
efforts. To educate and raise awareness about 
TB, CDC’s Division of Tuberculosis Elimination 
(DTBE) and others plan events each year for 
World TB Day, March 24. 
 
This year CDC selected as its World TB Day 
theme, “Find TB. Treat TB. Working together to 
eliminate TB.” CDC wanted to highlight the fact 
that TB is still a life-threatening problem in the 
United States, despite the declining number of 
TB cases. Anyone can get TB, and our current 
efforts to find and treat latent TB infection and TB 
disease are not sufficient. Misdiagnosis of TB still 
exists, and health care professionals often do not 
“think TB.” 
 
On March 24, CDC hosted a Twitter chat in 
recognition of World TB Day. The chat was 
moderated by CDC’s Center for Global Health. 
Dr. Phil LoBue, DTBE Acting Director, and Dr. 
Jonathan Mermin, NCHHSTP Director, shared 
their knowledge and expertise. CDC was also 
joined by USAID Global Health. The chat served 
to raise awareness about the progress being 
made to control and eliminate TB, and 
participants highlighted the ongoing work of CDC 
and USAID to increase prevention and treatment 
around the world. Utilizing the hashtag 
#TBDayChat, the hour-long event engaged 
approximately 707 Twitter users, and the 
messages potentially reached close to 8,000,000 
users.  
 
There were 78 promotional tweets, including 61 
retweets, containing #TBDayChat posted from 
March 17, 2014, through March 23, 2014. These 
promotional messages were posted by 61 
participants resulting in a potential reach of 
1,192,863 Twitter users. A summary of the 




—Reported by Nicole Richardson-Smith, MA 
Div of TB Elimination 
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USAID Honors Dr. Ken Castro’s 
Contributions to Global TB 
Control 
 
During a whirlwind week of activities 
commemorating World TB Day 2014, the U.S. 
Agency for International Development (USAID) 
honored Rear Admiral Ken Castro, MD, with a 
Lifetime Achievement Award.  The recognition 
ceremony was held at the Corcoran Gallery of Art 
in Washington, DC, on March 25, 2014.   
 
Kojo Nnamdi, host of the “The Kojo Nnamdi 
Show” on the Washington, DC, radio station 
WAMU and someone who has experienced TB 
within his own family, was the Master of 
Ceremonies for the event attended by several 
hundred. USAID’s Assistant Administrator for 
Global Health, Dr. Ariel Pablos-Méndez, and 
RESULTS’ Executive Director, Joanne Carter, 
shared the privilege of introducing each of the 
individuals who received awards.  Other 
Champions in the global fight against TB 
acknowledged by USAID included: 
 
• Senator Sherrod Brown (OH); 
• Representative Kay Granger (TX, 12th 
district); 
• Representative Eliot Engel (NY, 16th district); 
• His Excellency Mr. Heng Hem, Ambassador 
to the U.S. from the Royal Kingdom of 
Cambodia; 
• The Consortium to Respond Effectively to 
the AIDS and TB Epidemic (CREATE)—Dr. 
Richard Chaisson accepted the award on 
behalf of CREATE; 
• The British Academy of Film and Television 
Arts (BAFTA)–award winning producer Jezza 
Neumann, whose documentary TB: Silent 
Killer aired on PBS in March; and 
• TB survivors who were in Washington to 
participate in various World TB Day events 
on Capitol Hill. 
 
The last award of the evening, the Distinguished 
Lifetime Award, was reserved for Dr. Castro, and 
as Mr. Nnamdi called Dr. Castro on stage he 
called him a “TB Superstar.”  In his introductory 
comments, Dr. Pablos-Méndez identified Dr. 
Castro as a physician-scientist, known for his 
ability to work with people, his leadership skills, 
and his dedication to the fight against TB, 
spanning almost 30 years. Dr. Pablos-Méndez 
said Dr. Castro’s was “a life story of success” and 
expressed the hope that, although Dr. Castro 
was retiring from the CDC Commissioned Corps, 
“his leadership, talent, and friendship could 
continue to be tapped,” as the work to end TB 
was not finished.  
 
In accepting the award, Dr. Castro said that he 
was “deeply honored, humbled, and grateful,” 
then added, with the irreverent humor for which 
he is known, that “since he was not dead…the 
lifetime achievement award was for what had 
been achieved during his lifetime in a uniform.” 
Dr. Castro pledged his intent to continue fighting, 
with a full beard, not resting in retirement, as 
there was still work to be done. He dedicated the 
award to those we have been called on to 
serve—TB survivors—“who have lent their much-
needed voices to what has been a fairly faceless 
disease in this country.”  He accepted the award 
on behalf of all of those working to identify and 
locate people affected with TB so life-saving 
treatment could be provided. He concluded his 
remarks by acknowledging the work of his 
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colleagues at CDC who are united in the purpose 
of eliminating TB.   
 
As Dr. Castro completes his remaining few 
months in a uniform, we recognize that USAID is 
just one of many organizations who will publicly 
acknowledge the contributions he has made to 
domestic and global TB control efforts. Although 
many awards have been and will be bestowed on 
our colleague and friend, perhaps the most 
meaningful gift he will receive is one that we can 
give him—continuing his legacy of dedicated 
work for those individuals and their families who 
are impacted by the disease. The promise of a 
truly TB-free world, and Dr. Castro’s commitment 
to this end, should be our constant motivation. 
 
—Submitted by Donna Hope Wegener 
National TB Controllers Association 
 
DTBE Celebrates World KC Day! 
 
On March 28, 2014, 
the staff of DTBE 
gathered at CDC’s 
Corporate Square 
campus to bid 
farewell to Dr. Ken 
Castro. Dr. Castro 
served as the Director 
of DTBE for 20 years. 
In August 2013 he 
began serving a detail 
as Acting Director of 
the Division of 
HIV/AIDS Prevention. 
At the end of 2013, he 
vacated the position 
of DTBE Director to allow the Division to begin 
the process of filling the position, rather than 
waiting for his detail to end. To say farewell, the 
Division pitched in to create an appreciation 
event and to celebrate all things Ken Castro. All 
aspects of the event were made, bought, or 
contributed by CDC volunteers; no CDC funds 
were used.  
 
The planning committee arranged a stellar line-
up of speakers for the event. Dr. Jim Curran 
served as the Master of Ceremonies. The guest 
speakers included Dr. Phil LoBue; Dr. Lee 
Reichman (he was unable to attend; Dr. Wanda 
Walton presented his remarks instead); Dr. Mario 
Raviglione (via prerecorded video); and Dr. Jono 
Mermin. Dr. Wanda Walton presented a slide 
show that she and Cheryl Tryon had developed 
from photos that current and former colleagues 
had sent in. Much like at a celebrity “roast,” Dr. 
Castro was gently ribbed and reminded about 
numerous events and issues he’d had the 
privilege of dealing with over the years in his time 
as DTBE Director.  
 
Dr. Mario Raviglione’s presentation consisted of 
a mock interview he conducted with Dr. Castro, 
videotaped at WHO headquarters in Geneva. It 
was actually Dr. Raviglione speaking in a warm 
and friendly manner to a large doll propped up in 
a chair and wearing a Ken Castro face mask. 
With a twinkle in his eyes, Dr. Raviglione spoke 
to Dr. Castro’s doppelgänger about their 
experiences together in international TB control 
over the years. 
 
Since the theme was World KC Day, the event 
planners were able to highlight multiple  facets of 
Dr. Castro’s character, such as his Puerto Rican 
heritage; his international travels and friendships; 
and last but not least, his on-again, off-again 
relationship with facial hair, owing to a particular 
Commissioned Corps change in regulation about 
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grooming standards (i.e., beards were out). The 
decorations featured globe-like lanterns and 
grass-skirted tables, the food was island-themed, 
and guests were encouraged to wear tropical 
shirts. As a nod to the facial hair motif, there was 
a tray of chocolate mustaches to wear, or eat, or 
both. 
 
At one point in the festivities, in the midst of the 
planned agenda, a small group of people burst 
into the room and charged to the front, where 
they proceeded to serenade Dr. Castro. The 
group sang parodies of traditional Puerto Rican 
songs that they rewrote for Ken. For the last one, 
the whole gathered crowd was invited to sing 
along.  
 
Dr. Eugene McCray presided over the official 
presentation of gifts to Dr. Castro. These 
included an engraved plaque and a handsome 
crystal globe trophy that represented his 
influence in global TB control. 
 
There were other gifts as well. Dr. Andy Vernon 
presented him with a Ken Castro bobble-head 
doll, which came complete with Commissioned 
Corps uniform, eye glasses, and of course, facial 
hair. On behalf of the Field Services and 
Evaluation Branch (FSEB), Dr. Terry Chorba 
presented him with a medal originally made for 
the International Congress on Tuberculosis held 
in 1908 in Washington, DC. The medal, one of 
only a few that were made, had been 
commissioned by President Theodore Roosevelt 
as president of the International Congress. It was 
designed by Victor D. Brenner, who later 
sculpted the Lincoln penny. The medal depicts 
the allegorical female figure Lumen (Light), 
symbolic of science, standing with both arms 
raised. In one hand she is holding a winged hour-
glass of time, and she is trampling underfoot the 
dragon of the white death. (It will appear as the 
featured artwork on the cover of Emerging 
Infectious Diseases next March to coincide with 
World TB Day.)  
 
The event was well-attended. We were happy to 
see Dr. Castro’s wife Irene, daughters Ivonne, 
Laura, and Sara, son-in-law Sergio, and three 
grandchildren at the event. Many current and 
former DTBE staff showed up to wish Dr. Castro 
farewell and good luck. And arrangements were 
made so that field staff could participate 
remotely.  
 
We think Dr. Castro enjoyed the World KC Day 
event and appreciated the planning, the effort, 
and the high esteem that were reflected in it. 
 
—Reported by Ann Lanner 
Div of TB Elimination 
 
2014 EIS Conference 
 
The 2014 Epidemic Intelligence Service (EIS) 
Conference was held April 28 to May 1, 2014, in 
Atlanta. We are pleased that this year’s 
conference again contained a session dedicated 
to TB. 
 
Three EIS officers from DTBE’s International 
Research and Programs Branch (IRPB) were 
featured during the session, which was held on 
Tuesday, April 29. First year officers Dr. Tyson 
Volkmann presented “Tuberculosis and Excess 
Alcohol Use in the United States, 1997–2012” 
and Dr. Aditya Sharma presented 
“Characterization of Tuberculosis due to 
Mycobacterium africanum — United States, 
2004–2012”; second year officer Dr. Niki Alami 
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presented “Childhood Tuberculosis — Botswana, 
2008–2012.” 
 
Additional presentations were given by state-
based officers from the Division of Scientific 
Education and Professional Development 
(DSEPD), including “Opportunities for Improved 
Detection and Treatment of Latent Tuberculosis 
Infection Among Veterans — Western United 
States, January 2010–July 2013,” presented by 
Dr. Tara Perti, and “Contact Investigation of 
Healthcare Personnel Exposed to Maternal and 
Neonatal Tuberculosis — Clark County, Nevada, 
2013” given by Kaci Hickox.  
 
In addition, first year officer Dr. Erik Reaves from 
DTBE’s Surveillance, Epidemiology, and 
Outbreak Investigation Branch presented 
“Strategies for Maximizing Preventive Treatment 
of Latent Tuberculosis Infection — Mississippi, 
2008–2012” in the newly updated poster 
symposium session held on Monday, April 28.  
Dr. Reaves provided a 2-minute synopsis of his 
work to accompany the poster that he presented.  
Dr. Jessica Adam, a state-based officer from the 
DSEPD, also presented on “Mexican-Born Legal 
Immigrants with Tuberculosis Classifications 
Using Electronic Disease Notification Database, 
2009–2012.” During the poster symposium 
session held on Tuesday, Dr. Abbey Canon, also 
from DSEPD, presented “Delayed Diagnosis of 
Multidrug-Resistant Tuberculosis and the 
Resulting Outbreak — Sheboygan, Wisconsin, 
2012–2013.” All presentations were well-received 
and generated enthusiastic responses and 
discussions.  Congratulations to everyone on a 
job well done! 
 
DTBE also had very successful matches this 
year. Two new EIS officers are coming into IRPB: 
Hannah Kirking and Colleen Scott. One new 
officer is coming into SEOIB: Godwin Mindra. We 
are looking forward to working with these new 
officers. 
 
—Reported by Tracie Gardner, PhD 
Div of TB Elimination 
TB EDUCATION AND TRAINING 




2014 TB ETN and TB PEN Conference 
 
The 13th Tuberculosis Education and Training 
Network (TB ETN) Conference, “The Changing 
Landscape of TB,” will be held in Atlanta, 
Georgia, September 16–18, 2014, at the CDC 
Global Communication Center (GCC). For the 
fifth year, TB ETN and the Tuberculosis Program 
Evaluation Network (TB PEN) will join forces to 
explore the common aspects of TB education, 
training, and evaluation. 
 
The purpose of this year’s conference is to 
highlight recent changes in TB control and 
prevention and discuss the implications for TB 
education, training, and program evaluation. 
Conference activities will include skills-based 
workshops, informational presentations, and 
networking opportunities. Included in the 
conference agenda will be the Education and 
Training Focal Point Meeting and the Program 
Evaluation Focal Point Meeting. 
 
The conference and meetings are an important 
gathering of designated education and training 
and program evaluation focal points where they 
receive updates and guidance from CDC. 
There’s no registration fee for this conference. All 
interested persons are welcome to attend. For 




—Reported by Peri Hopkins, MPH 
Div of TB Elimination 
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CLINICAL RESEARCH BRANCH 
UPDATES 
 
Summary of March TBTC Meeting 
 
The Tuberculosis Trials Consortium (TBTC), a 
CDC-sponsored collaboration in TB clinical trials, 
is composed of clinical investigators from 
academic medical centers, health departments, 
and U.S. Department of Veterans Affairs medical 
centers located in the United States, Hong Kong, 
Kenya, Peru, South Africa (2 centers), Spain, 
Uganda, and Vietnam. The TBTC mission is to 
conduct programmatically relevant research 
concerning the diagnosis, clinical management, 
and prevention of tuberculosis infection and 
disease. These centers work in collaboration with 
Division of Tuberculosis Elimination (DTBE) staff 
to perform Phase II and Phase III clinical trials 
and pharmacokinetic studies in TB treatment and 
prevention. The consortium normally meets 1–2 
times a year to provide study updates to 
Consortium members, to perform needed training 
for ongoing or upcoming studies, to review new 
developments in TB therapeutics and in clinical 
trials, and to allow a large number of TBTC work 
groups to meet in person. 
 
During March 17–19, 2014, TBTC members 
gathered in Decatur, Georgia, for the 34th semi-
annual meeting. Over 125 participants 
representing clinical research sites, academia, 
pharma, WHO, other TB clinical trials groups, 
and other federal agencies attended this year’s 
meeting. 
 
On March 17, the consortium’s Community 
Research Advisory Group (CRAG) met to review 
directions for TB therapeutic research, provide an 
update on these community representatives, and 
develop their work plan. That same day, there 
were 6 hours of protocol training for coordinators 
involved in the new Study 36 Platform study. The 
group’s Executive Affairs Group also met. 
 
On March 18, the TBTC met in plenary to review 
progress on Study 26 and the 3HP sub-studies, 
including updates on the hypersensitivity and 
post-marketing studies.  Drs. Andrey Borisov and 
Bob Belknap summarized the status of Study 
33/iAdhere, which is evaluating self-
administration of the 3HP regimen for LTBI. 
Diagnostic activities were reviewed as part of the 
Study 34 and Study 29X Gene Xpert updates. Dr. 
Anneke Hessling presented on treatment 
markers in children. That afternoon, eight work 
groups, committees, and protocol teams 
convened for working meetings (Adverse events, 
Pharmacokinetics, LTBI, Phase 2, Microbiology 
and Diagnostics, Study 33, and Core Science, 
Advocacy and External Relations), in addition to 
a meeting of site coordinators. 
 
The March 19 plenary focused on active TB 
disease. Dr. Susan Dorman summarized 
outcomes for Hopkins’s studies of moxifloxacin 
and rifapentine in Rio and Cape Town.  Prof. 
Andrew Nunn from the UK Medical Research 
Council offered a perspective on phase 3 TB 
clinical trials. Dr. Christian Lienhardt provided an 
update on WHO’s effort to assure rational 
introduction of new drugs. Dr. Dan Everitt shared 
the phase 3 perspective of the TB Alliance. A 
series of presentations reviewed activities 
involving rifapentine: Dr. Marilyn Maroni from 
Sanofi presented findings from their rifapentine-
efavirenz interaction study, Dr. Marc Weiner 
shared recent findings from TBTC work on 
pharmacokinetic and pharmacodynamic studies 
of rifapentine, and Dr. Payam Nahid presented 
and led a discussion on the planned phase 3 
study of high-dose rifapentine-based 4-month 
therapy for TB disease (TBTC Study 31). Drs. 
Mike Vjecha and Debra Benator discussed the 
platform diagnostic study and projects (Study 36 
and 36A), and Drs. Jason Stout and Kelly Dooley 
summarized the state of the group’s phase 2 
plans. That afternoon, six work groups, teams, 
and committees convened (Biomarkers, Study 31 
team, MDR, Study 35 [pediatric pharmaco-
kinetics of rifapentine], Core Science, and EAG). 
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The following day, the protocol team for Study 32 
had a day-long meeting and training session. 
Study 32 (Opti-Q) involves optimization of dosing 
of levofloxacin in MDR treatment. 
 
One highlight of this year’s meeting was the 
recognition of Dr. Fred Gordin for his more than 
25 years of leadership and service to CDC and 
TBTC. An award was presented by Dr. Jonathan 
Mermin, Director of NCHHSTP. In addition, Alicia 
Wright, R.N., from Vanderbilt University was 
recognized with the Sandman-Tapy Award for 
outstanding performance by a Clinical Nurse 
Coordinator. 
 
The TBTC meetings are open and public 
meetings. For more details, please contact Andy 
Vernon, Beverly Devoe Payton, Stefan Goldberg, 
Bill Mac Kenzie, or Lorna Bozeman in DTBE’s 
Clinical Research Branch. 
 
—Submitted by Beverly DeVoe Payton 
Div of TB Elimination 
 
Updated Cost-Effectiveness Analysis 
for 12-Dose Regimen 
 
Dylan Shepardson, former Prevention 
Effectiveness Fellow in DTBE, published a letter 
in the International Journal of Tuberculosis and 
Lung Diseases (IJTLD) that updates the cost-
effectiveness analysis for the 12-dose regimen 
for LTBI treatment. This analysis is based upon 
the lower price for rifapentine offered by Sanofi. 
The letter includes reference to a website where 
TB program staff can input local costs for various 
elements to best inform local policy for the use of 
the 12-dose regimen. 
 
Though Dylan has returned to Mount Holyoke, 
we are fortunate that he continues to engage in 
DTBE modeling projects. 
 
—Reported by William Mac Kenzie, MD 
Div of TB Elimination 
Reference 
Shepardson D, Mac Kenzie WR. Update on cost-
effectiveness of a 12-dose regimen for latent 
tuberculous infection at new rifapentine prices. 







DTBE Staff Assist WHO in Training-
of-Trainers Workshop 
 
Wanda Walton, PhD, and Cheryl Tryon, MS, of 
DTBE’s Communications, Education, and 
Behavioral Studies Branch (CEBSB), assisted 
the World Health Organization (WHO) Global TB 
Programme in organizing and implementing a 
training-of-trainers workshop for the 
Programmatic Management of Drug-Resistant 
TB (PMDT). The workshop was held in 
conjunction with the WHO South East Asia 
Region Office (SEARO) in New Delhi, India, from 
March 18 to 27, 2014. Walton and Tryon also 
conducted this same training with WHO in the 
Philippines in May 2013. The overall goal of the 
workshop was to create a cadre of master 
trainers in the region who will be able to deliver 
high-quality training in their own countries for 
health-care workers responsible for implementing 
services to diagnose and treat multidrug-resistant 
(MDR) TB. 
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The training was based on MDR TB technical 
modules developed by WHO, using the CDC 
Teachback Methodology Curriculum to develop 
training skills for the participants. The 21 
participants included representatives of national 
TB programs, WHO country offices, and 
nongovernment organizations from Bangladesh, 
Bhutan, India, Indonesia, Myanmar, Nepal, Sri 
Lanka, Thailand, and Timor-Leste who are active 
in providing TB-related training. Each participant 
developed a country-specific human resource 
development plan for PMDT requirements in their 
own country, and each is expected to follow up 
with implementation of the plan after the 
workshop. 
 
—Reported by Wanda Walton, PhD, 
and Cheryl Tryon, MS 
Div of TB Elimination 
 
Dr. Mase Provides Expert 
Commentary for Medscape on MDR 
TB and Bedaquiline 
 
Medscape from WebMD provides medical news 
features, commentary, and reference content for 
physicians, nurses, pharmacists, and other 
health professionals. CDC and Medscape 
collaborate to produce a special series of CDC 
expert commentaries designed to deliver 
guidance directly to Medscape's physicians and 
other health-care professionals. In this series, 
experts from CDC offer video commentaries on 
current topics. 
 
In March 2014, DTBE participated in the CDC 
Expert Commentary Series. Dr. Sundari Mase, 
Medical Team Lead in the Field Services and 
Evaluation Branch, DTBE, recorded the 
commentary, New Drug Available to Treat 
Multidrug-Resistant Tuberculosis, at CDC’s 
broadcast studios in Atlanta. This commentary 
details the recently released CDC guidelines for 
the use and monitoring of the new TB drug 
bedaquiline. The commentary was posted on 
March 31, 2014, on Medscape’s website where it 
can be viewed after a short registration process. 
As an alternative, it can be viewed on the DTBE 
website on the Drug-Resistant TB webpage. 
 
Other examples of Medscape’s CDC Expert 
Commentary Series, including the 2011 
commentary recorded by former DTBE Director 
Dr. Kenneth Castro titled, What’s New in Blood 
Testing for TB Infection?, and the 2012 
commentary he recorded titled, New Regimen 
Makes Treating Latent Tuberculosis Infection 
Easier. Both of these are available on 
Medscape’s “CDC Expert Commentary ” 
webpage. 
 
—Reported by Nicole Richardson-Smith, MA 
Div of TB Elimination 
 
The cookie elves are a little confused. 
 
N-95 masks are not usually needed when 
cookies are on the menu. But these were no 
ordinary cookies; they were World TB Day 2014 
cookies! 




These lung-shaped sugar cookies with lemon 
flavored icing made a tasty treat for the staff in 
the Division of Tuberculosis Elimination. Each 
cookie carried a note thanking the DTBE staff for 
all they do to find, treat, and eliminate TB. 
 
—Reported by Joan Mangan, PhD, MST 
Div of TB Elimination 
 
Editor’s note: Dr. Joan Mangan is the same 
mad(ly creative) scientist who made the 




AND PROGRAMS BRANCH 
UPDATES 
 
Improving the Quality and Usage of 
TB Surveillance Data — Uganda 
 
Background: The development and maintenance 
of robust national-level TB surveillance systems 
is a priority in TB control.1,2  Strong surveillance 
systems can be used to improve planning and 
monitoring of interventions and progress towards 
TB program targets, while weak surveillance 
systems can shroud or hinder programmatic 
successes. Nonetheless, maintaining quality TB 
surveillance data remains a challenge in many 
countries, with issues such as underreporting 
being widespread.2 This makes it difficult to 
recognize the true burden of TB and thus plan 
and provide the programs necessary for optimal 
TB control.  
 
In Uganda, one of the world’s 22 high TB-burden 
countries,2 an evaluation using the World Health 
Organization’s Checklist of Surveillance 
Standards and Benchmarks identified gaps in 
national TB surveillance, namely high 
underreporting and lack of data use. To close 
these gaps and strengthen the national TB 
surveillance system, the Uganda National TB and 
Leprosy Programme (NTLP) collaborated with 
DTBE/IRPB and the African Field Epidemiology 
Network to develop and implement an 
intervention for all NTLP staff called TB Data – 
Improving Quality and Usage (TB-IQu). 
 
Intervention: The Performance of Routine 
Information System Management (PRISM) 
framework3,4 guided the development of TB-IQu. 
The PRISM framework proposes that data quality 
and information use are affected by technical, 
organizational, and behavioral factors, all of 
which this intervention was designed to address. 
In addition, key principles for building improved 
health information systems were followed (e.g., 
focus on empowerment, local ownership, using 
existing infrastructure),5 while lessons learned in 
other health sectors were built upon.6,7   
 
On the technical side, systems and tools were 
created to prioritize data quality and usage. The 
format for data presentation at subnational 
quarterly TB meetings was revised to promote 
critical peer-reviews of data. To do this, a new, 
automated template was created to enable 
subnational staff to easily create and present 
basic time-series analyses of key TB 
epidemiologic and programmatic variables. As 
this new system relies on analyzing trends over 
time, unexplained changes highlight where 
reporting errors are likely. This increases the 
usefulness of data for subnational staff and 
encourages the responsible TB staff to examine 
suspect data. As a result, the quality of data that 
reach the central level improves.  
 
On the organizational side, a systematic 
approach to data audits and checks was 
developed along with standard operating 
procedures (SOPs) for all data-related tasks.  To 
promote adherence, these SOPs are in the 
process of being organized in a desk guide for 
staff, with select SOPs to be displayed as posters 
for placement in relevant offices.   
 
On the behavioral side, a training-of-trainers 
workshop curriculum was designed to enable 
staff to practice using new tools and procedures 
NUMBER 2, 2014 
16 
 
and guide subnational TB staff to value the 
importance of quality data. To foster sustainable 
change, the workshop consists of group 
discussions and hands-on practice. 
 
Initial results: TB-IQu rollout is ongoing. To date, 
the tools and processes of this intervention have 
been reviewed by various stakeholders and 
piloted among approximately 20 national and 
zonal (i.e., provincial) TB staff at a 3-day 
workshop in December 2013. Based on group 
evaluations, participants viewed this workshop to 
be successful at raising awareness of the need to 
increase the quality and use of data, especially at 
the subnational level. In particular, staff members 
were enthusiastic about using the new quarterly 
analysis template to analyze and present time-
series analyses on subnational data. This was 
the first time they had used graphs to view their 
data and examine data over time. They were 
surprised to discover that this approach revealed 
inconsistent trends in their data, which were likely 
due to unrecognized problems with recording and 
reporting. These findings spawned lively group 
discussions on problems about and potential 
solutions for data quality. 
 
Staff unanimously indicated that this training 
added meaning to the data they collected and 
enabled them to view and interpret data in new 
ways. In particular, they expressed strong 
interest in the quarterly analysis template 
because it allowed even those with minimal 
computer literacy to turn raw data into usable 
information. However, they said that additional 
training and simplification of the tool would be 
needed to ensure acceptance and use by all 
subnational staff. 
 
Next steps: At this time, the Uganda NTLP is 
making plans to roll out TB-IQu to district-level 
staff. As this roll-out happens, IRPB will provide 
assistance in monitoring and improving the 
acceptance and viability of TB-IQu over time. 
Meanwhile, DTBE/IRPB is collaborating with 
programs in South Africa to adapt and implement 
TB-IQu, as it is anticipated that TB-IQu can be 
easily adapted for use in other countries that are 
also hoping to strengthen national TB 
surveillance and improve estimates of TB 
incidence.   
 
For more information, contact Deanna Tollefson 
(vtu3@cdc.gov).  
 
—Reported by Deanna Tollefson, MPH 
Div of TB Elimination 
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The Tuberculin Skin Test and the 
Risk of Death Among Patients With 
Active TB 
 
In 1890, Dr. Robert Koch announced he had 
found a cure for TB: the tuberculin protein. 
Despite falling short of that initial claim, over the 
last 120 years, the tuberculin skin test (TST) has 
been widely adopted to screen for infection with 
TB and to identify latently infected individuals 
who may benefit from TB preventive therapy.1 
However, it is important to remember that the 
TST is not a perfect test. The induration that is 
measured as the “readout” of a TST is dependent 
upon not only the presence of the tuberculin 
protein, but also the host immune response to 
the tuberculin.  
 
Approximately 10%–25% of patients with TB 
disease have a negative TST result.2,3 Patients 
with TB disease who have a negative TST result 
are unable to mount the host immune response 
necessary to generate induration. Young children 
and people with HIV infection who develop TB 
disease are more likely to have a negative TST 
and more likely to present with severe disease.1 
Studies have also found that young children and 
people with HIV infection who have TB disease 
and a negative TST result have an increased risk 
of death.4,5 The association between a negative 
TST result and death has also been reported in 
smaller studies of immunocompetent adults, but 
the nature of this relationship remains poorly 
understood.6,7  
 
We conducted a study to determine the 
association between TST result and the risk of 
death among persons with TB disease in the 
United States. For the period January 1, 1993, 
through December 31, 2008, we looked at all 
cases of TB reported through the National 
Tuberculosis Surveillance System with a positive 
TB culture result at baseline and a documented 
TST result who had either completed TB therapy 
or died of any cause after initiating therapy. In 
order to account for many of the factors that are 
known to influence the host immune system or 
the TST result, we adjusted our analysis for HIV 
status, origin of birth (i.e., U.S. born or foreign 
born), age, sex, location of TB disease (e.g., 
pulmonary, extrapulmonary), and presence of 
cavities on chest x-ray. We also examined cases 
based on their baseline drug-susceptibility test 
results, using three categories: 1) susceptibility to 
all four first-line TB drugs (isoniazid, rifampin, 
pyrazinamide, and ethambutol), 2) resistance 
only to isoniazid, or 3) multidrug-resistant (MDR) 
TB with resistance to at least rifampin and 
isoniazid. We found that patients with TB disease 
and a negative TST result are two to three times 
more likely to die than patients with a positive 
TST result, despite adjusting for important 
covariates. These findings were consistent 
across the three drug-susceptibility categories.  
 
Our results are consistent with prior studies 
suggesting that patients with a negative TST are 
at greater risk of death; based on this analysis, 
we recommend using the TST for both routine 
clinical practice and as a part of TB research 
activities. In addition to serving as an indicator of 
latent TB infection, a negative TST result 
appears to be a marker for risk of death among 
patients with active TB disease. 
 
—Reported by Sara Auld, MD 
Div of TB Elimination 
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Laboratory Webinar: Best Practices 
for Genotyping Submission 
 
On April 10, 2014, DTBE’s Laboratory Branch 
and the Michigan Department of Community 
Health (MDCH), Bureau of Laboratories, hosted 
a webinar highlighting the proper shipping of 
specimens to MDCH for genotyping. The webinar 
also showcased the work that the Michigan 
public health laboratory performs under its 
contract with CDC to provide genotyping services 
to TB programs in the United States. TB 
programs may submit one isolate from each 
patient culture positive for TB within their 
jurisdictions to the Michigan laboratory as part of 
the CDC Tuberculosis Genotyping Program. 
 
MDCH has a long history with the TB genotyping 
program, beginning in 1996 as a participant in 
the National Genotyping and Surveillance 
Network. At that time, MDCH performed IS6110-
based restriction fragment length polymorphism 
(RFLP) analysis and spoligotyping. In 2003, 
Michigan was one of two states awarded a 
contract with CDC to perform spoligotyping, 
mycobacterial interspersed repetitive unit - 
variable number of tandem repeat  analysis 
(MIRU-VNTR), and RFLP testing for TB 
programs in all states east of the Mississippi. In 
October of 2013, Michigan was awarded the sole 
contract to perform MIRU-VNTR for all TB 
programs in the United States. The new model 
requires Michigan to receive approximately 9,000 
isolates per year, extract DNA, perform MIRU-
VNTR, and send a portion of the DNA to CDC for 
spoligotyping. The goal of MDCH is to provide 
MIRU-VNTR results within 5 days of receipt in 
the laboratory.  
 
The genotyping webinar served as a refresher for 
public health laboratories to highlight the best 
practices for shipping isolates of M. tuberculosis 
complex (MTBC) to MDCH for genotyping. 
Sending isolates that are correctly prepared, 
identified, packaged, and shipped serves to 
facilitate the prompt testing of these isolates and 
also ensures the safety of testing personnel. 
Isolates of MTBC are considered Category A 
Infectious Substances, and as such, their 
transport is governed by rules set forth by both 
the Department of Transportation and 
International Air Transport Association.  
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Some of the information provided in the webinar 
included: 
• Types of cultures to send for best results, 
including proper media, growth requirements, 
and age of isolates; 
• Proper use of Category A shipping 
containers; 
• Paperwork needed prior to testing, including 
shipping forms and TB GIMS sheets; 
• Appropriate use of the CDC Fed-Ex account 
for no-cost shipping; 
• Conditions for return of shipping containers; 
and 
• Explanation of MIRU protocol and turnaround 
time. 
 
Personnel from MDCH presented an informative 
and interesting webinar that was well attended by 
state and local public health laboratories across 
the county. If you missed the webinar, and would 
like the handouts associated with the 
presentation, please contact: Frances Tyrrell, 
ftyrrell@cdc.gov 
 
—Submitted by Angie Schooley, MT (ASCP) 
and James Rudrik, Ph.D. 
Michigan Department of Community Health, and 







Update from the Molecular 
Epidemiology Activity: New Tools to 
Improve Data Quality in the TB GIMS 
System  
 
Do you use genotyping information routinely in 
TB control activities?  
 
If so, you know that the Tuberculosis Genotyping 
Information Management System (TB GIMS) is a 
secure web-based system that is used to 
manage genotyping data for persons with 
culture-positive TB in the United States. And you 
also understand the importance of linking 
genotype results to surveillance records in TB 
GIMS. This linkage is necessary for genotype 
results to be available in TB GIMS reports, maps, 
and searches. 
 
In the new release of TB GIMS version 1.10 
(March 2014), two additional reports were 
included to facilitate TB GIMS Super Users in 
linking genotype results to surveillance records. 
Local and state TB programs can increase their 
genotyping surveillance coverage and improve 
data quality with the 1) ‘Unlinked Isolates’ and 2) 
‘Not Culture-Positive’ reports.  
 
The ‘Unlinked Isolates’ report identifies isolate 
records that have text entered into the State 
Case Number field, but are not linked to a 
surveillance record. These isolate records might 
not be linked due to an error in the State Case 
Number, or because the surveillance record 
hasn’t been transmitted to CDC, or because the 
isolate record does not have a corresponding 
surveillance record. 
• When the State Case Number is corrected 
and the surveillance record is transmitted to 
CDC, the isolate record will be linked.  
• If the isolate record is not expected to be 
linked to a surveillance record (e.g., if the 
isolate is from an out-of-state case or not 
related to a TB case), users can manage this 
information by changing the status to ‘Not 
linkable.’  
 
The ‘Not Culture-Positive’ report identifies 
surveillance records that were not reported as 
having a positive culture result, but were linked to 
an isolate record with a genotype result.  
• Because genotyping can only be performed 
on isolates with culture-positive results, 
either the culture status for the case or the 
linking information should be corrected. 
 
By reviewing these reports and coordinating with 
surveillance partners to resolve these issues on a 
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quarterly basis, state and local TB control 
partners can ensure that accurate and timely 
genotyping data are available in TB GIMS.  
 
Good quality genotype and surveillance data will 
not only augment TB surveillance, but also 
support and encourage use of genotyping data 
for TB outbreak detection and response activities 
in the United States.  
 
—Reported by Smita Ghosh, MS 
Division of TB Elimination 
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The Antibiotic Resistance Threat Report Team 
received a CDC honor award in the category 
Excellence in Communications. The team has 
also been nominated for an HHS award. They 
were recognized for their important work at the 
62nd annual CDC Honor Awards ceremony on 
May 13. DTBE staff members who are part of this 
team include Peter Cegielski, Suzanne Marks, 
Roque Miramontes, Robert Pratt, Wanda Walton, 
and Michael Iademarco (formerly of DTBE). 
 
Jose Becerra, MD, MPH, F.A.C.P.M., a retired 
captain of the USPHS Commissioned Corps, 
retires this summer from government service 
after 33 years of service with the U.S. Public 
Health Service (USPHS). He has served 29 
years with CDC, of which 19 years were with 
DTBE in the National Center for HIV/AIDS, Viral 
Hepatitis, STD, and TB Prevention. 
 
In 1975, Dr. Becerra received a National Health 
Service Corps (NHSC) scholarship to the 
University of Puerto Rico (UPR) School of 
Medicine. After graduating and completing 1 year 
of residency in Internal Medicine at the VA 
Hospital in San Juan, Puerto Rico, he completed 
his NHSC commitment by serving 4 years (1979–
1983) in the USPHS. He served as an NHSC 
Medical Officer, a Medical Director, and a Clinical 
Preceptor in two primary care clinics in Maunabo, 
Puerto Rico (1979–1980), and in Cidra, Puerto 
Rico (1980–1983). 




From 1983 to 1985, he earned an MPH in 
epidemiology and biostatistics at San Diego 
State University and completed his California 
preventive medicine residency. By then he had 
found his career path: The Cidra Migrant Health 
Project, affiliated with the UPR School of Public 
Health, had opened up for him the field of 
preventive medicine and public health. 
 
In 1985, Dr. Becerra entered the CDC Epidemic 
Intelligence Service (EIS) class of 1985 and 
joined the Division of Reproductive Health 
(DRH). In 1987, he was awarded a Public Health 
Service Citation for analytic proficiency in the 
study of childbearing, pregnancy risks, and infant 
mortality patterns, focusing on minority 
populations. After serving 1 year in the Division 
of Birth Defects and Developmental Disabilities, 
Dr. Becerra returned to DRH in 1988. 
 
In 1991, he was assigned by DRH to the 
Commonwealth of Puerto Rico Department of 
Health (PRDH) to direct the Puerto Rico Maternal 
and Child Health Epidemiology Program (PR-
MCHEP). In 1993, as part of this assignment, he 
was asked to direct the Division of 
Epidemiological Surveillance and Statistics 
(DESS). DESS had oversight responsibilities for 
three different disease registries (cancer, 
newborn screening, and premature thelarche) 
and for the PR-MCHEP. The new Division was 
created to apply the model successfully 
implemented by the PR-MCHEP to other areas 
within the PRDH. In 1993, Dr. Becerra received 
the PHS Surgeon General's Exemplary Service 
Medal for conducting studies related to the health 
status of mothers and children in Puerto Rico.  
 
In 1994, his functions were expanded to include 
directing the PR-MCHEP. As Director of the PR-
MCHEP, Dr. Becerra served as the 
Commonwealth Perinatal Epidemiologist. He also 
held an appointment as Associate Professor of 
Epidemiology in the UPR-GSPH. Dr. Becerra 
received the Public Health Service Achievement 
Medal for building the surveillance and research 
capacity of public health workers in Puerto Rico. 
 
From 1985 to 1995, Dr. Becerra participated in 
and coordinated international courses in 
reproductive health epidemiology and research 
methods in Latin America and Spain. He also 
conducted workshops at the UPR-GSPH and 
taught epidemiology to medical students.  
 
In 1995 Dr. Becerra returned to Atlanta, and 
since then has served as a senior advisor to 
DTBE on public health informatics and 
biostatistics. He was a founding member of the 
CDC Information Resources Governance 
Council, representing NCHHSTP through 2012. 
 
Dr. Becerra currently serves as Chief of DTBE’s 
Data Management and Statistics Branch 
(originally the Computer and Statistical Services 
Activity). He provides leadership and oversight to 
mission-critical DTBE functions related to data, 
information management, and LAN support; 
statistical, methodological, and epidemiological 
analyses; and software development and 
maintenance of the Tuberculosis Information 
Management System and its transition to a 
standards-compliant electronic system 
supporting the National TB Surveillance System.   
 
Since 1995, Dr. Becerra has participated in and 
coordinated the Operational Research and 
Epidemiological Methods training course for TB 
Program Managers in Vietnam, India, and Latin 
America. Most recently, Dr. Becerra has provided 
technical assistance to the National TB Program 
in the Dominican Republic to design, develop, 
test, and deploy a web-based TB surveillance 
system using the CDC Enterprise Performance 
Life Cycle model.  
 
Dr. Becerra’s undergraduate major in 
mathematics was put to the test as he led a team 
of statisticians to develop a mathematical model 
of TB transmission to guide policy decisions on 
TB elimination. The model was recently 
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published and has been widely cited domestically 
and internationally.  
 
During his retirement, José plans to be a frequent 
“snowbird” to his native Puerto Rico while 
keeping his main residence in Atlanta, where he 
and his wife Dr. Rosa B. Licha-de-Becerra home 
schooled and raised three wonderful children. 
 
DTBE celebrated Jose’s career on May 29. We 
thanked him for his many contributions to public 
health and bid him a very fond farewell as he 
launches this new phase of life. 
 
Emily Bloss, PhD, received the May 2014 
NCHHSTP Director’s Recognition Award. Over 
the past 2.5 years, Emily has worked with the 
WHO’s Global Task Force on Impact 
Measurement, exemplifying outstanding 
international collaboration and leadership in 
strengthening national TB surveillance systems, 
leading and supporting the development of 
guidance documents and tools, and supporting 
prevalence surveys in multiple countries. She 
has demonstrated exceptional skill in gaining the 
confidence and cooperation of partners with the 
Global TB Program at the WHO and has 
exceeded expectations by successfully and 
efficiently responding to the needs of both DTBE 
and WHO and facilitated collaboration and 
communication between the two organizations. In 
her role with WHO, Emily has contributed to the 
development of international guidelines for 
national TB prevalence surveys and inventory 
studies for assessing under-reporting, in which 
she helped define methods used for conducting 
these large studies. She also helped lead the 
development of internationally applied standards 
and benchmarks for TB surveillance. For her 
outstanding work and ability to lead and work 
with other leaders in TB control from many 
different countries, WHO and other key technical 
partners, as well as other U.S. government 
agencies to continue to improve surveillance 
systems, she receives the NCHHSTP Director’s 
Recognition Award. 
 
Kawi Mailutha has left IRPB to join the Center for 
Global Health. She will be working as a Public 
Health Analyst providing support and working 
with stakeholders to implement the Global Health 
Security agenda. Her last day in the office was 
May 16, 2014.   
 
Since joining IRPB in 2009 as a Public Health 
Analyst, Kawi has served in several key 
capacities. These included 1) serving as the 
project officer for cooperative agreements with 
the Civilian Research and Development 
Foundation, the Kenya Medical Research 
Institute for DTBE, and the World Health 
Organization (WHO), 2) serving as the country 
lead for Kenya and the administrative lead to 
IRPB’s Drug-Resistant TB (DR-TB) team, 3) 
leading and coordinating communication and 
education materials for the Branch for various 
publications and 4) serving as the DTBE liaison 
with the WHO TB Technical Assistance 
Mechanism (TBTEAM).   
 
Bonnie B. Plikaytis is retiring after 36 years of 
service for CDC. After reading about the work of 
CDC in solving the mysterious illness that killed 
29 individuals that attended the American Legion 
conference in Philadelphia in the summer of 
1976, it became her dream to work at CDC. In 
April of 1978 the dream came true as she began 
work in the special immunology laboratory 
working on the diagnosis of Legionnaires' 
disease. It was a tremendous experience for a 
23-year-old from Arkansas just out of her Medical 
Technology internship. The work was fascinating, 
working with the epidemiologists to solve the 
mystery of several additional outbreaks of 
Legionnaires' disease. On one such outbreak in 
1983, the work brought her in contact with a 
talented young statistician. The story goes that 
she not only got great statistical analytic service 
but found her husband to be, Brian. 
 
After the work with Legionnaires' disease, she 
spent many years studying Mycobacterium 
tuberculosis and in particular understanding the 
molecular mechanisms of drug resistance in M. 
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tuberculosis and how to apply it to the diagnosis 
of drug-resistant TB. There were many 
publications and a few patents, but her greatest 
joy was in sharing the thrill of discovery with 
those working under her when they solved a 
difficult problem or found the answer to an 
elusive question. It did not matter if the issue or 
question was related to program, policy, or 
science, as she understood and appreciated the 
importance of all three and how they were 
intertwined in the complicated work of public 
health. 
 
Her last 6 years were spent in management of 
the Laboratory Branch of the Division of 
Tuberculosis Elimination. Though it was hard for 
her to leave the research lab bench, she 
approached management with the same logic, 
dedication, and enthusiasm she applied to 
laboratory science. During her tenure as deputy 
and then acting branch chief, she provided the 
vision and laid the foundation for the current 
portfolio of branch activities, including the 
molecular detection of drug resistance service, 
applied research on mechanisms of drug 
resistance, and systems research to strengthen 
laboratory capacity. Importantly she also inspired 
hope and instilled confidence in the branch staff. 
After she left the lab bench, she lived vicariously 
through the staff entrusted to her and was always 
extremely proud of the groundbreaking work of 
the talented and dedicated individuals of the 
DTBE Laboratory Branch; work that continues to 
influence the field in a positive way. 
  
As she completes her time at CDC and takes on 
a new life adventure in Big Canoe with her 
husband Brian and two dogs, Decker and Hailey, 
she will fill her time with activities including 
family, friends, dogs, woodland gardening, and 
the great outdoors. As a person who has spent 
her life recognizing opportunities and connecting 
dots to develop strategies and accomplish tasks, 
there will be no lack of things to keep her busy. A 
reception to celebrate Bonnie’s extraordinary 
career will be held on Thursday, June 26 at 
CDC’s Roybal Campus. 
Chitvan Yadav, who is a front-end web designer 
and developer, has joined CEBSB and DTBE as 
a Web Master. Pursuing her lifelong interest in 
arts and creativity, she earned a bachelor’s 
degree in Fine Arts. She also earned an 
associate degree in web design and interactive 
media. During her studies, she completed 
numerous freelance projects, and after 
graduation, she was fortunate to work with AT&T 
and YP (The Yellow Pages). In her free time, she 
loves spending time with her family, and she 
enjoys painting and gardening whenever she has 
time. Chitvan is really pleased and excited about 
working at CDC and is looking forward to being 
part of the quality work carried out here.  
 
CALENDAR OF EVENTS 
 
June 22–26, 2014 
CSTE Annual Conference 
Nashville, Tennessee 
Council of State and Territorial Epidemiologists 
(CSTE) 
 
July 20–25, 2014 
AIDS 2014 - 20th International AIDS Conference 
20th International AIDS Conference, AIDS and 
HIV Medical Congress 
Melbourne, Australia 
 
Sept. 7–9, 2014 
American College of Epidemiology (ACE) 
Meeting 
Silver Spring, MD 
American College of Epidemiology 
 
September 9–11, 2014 
Albuquerque, New Mexico 
 Learn More » 
Association of State and Territorial Health 
Officers (ASTHO) 
 
Sept. 16–18, 2014 
TB ETN and TB PEN Joint Conference 
Atlanta, GA 
Peri Hopkins/Awal Khan 




Oct. 15–18, 2014 
The 51st Annual Denver TB Course 
Denver, Colorado 
The 51st Semi-Annual Denver TB Course - 
National Jewish Health 
 
Oct. 28–Nov. 1, 2014 
45th UNION World Conference on Lung Health 
Barcelona, Spain 
IUATLD 
Click here to download the Barcelona 2014 
Brochure   
Website:  http://barcelona.worldlunghealth.org 
  
Nov. 15–19, 2014 
142nd APHA Annual Meeting 
New Orleans, LA 
American Public Health Association (APHA) 
